文献速递肾移植

质子泵抑制剂泮托拉唑对肾移植和肝移植受者霉酚酸暴露的影响:一项随机试验

Effect of the proton-pump Inhibitor pantoprazole on MycoPhenolic ACid exposure in kidney and liver transplant recipienTs (IMPACT study): a randomized trial.
PubMed 文献 · Nephrol Dial Transplant · 2020-01-01

该多中心随机双盲安慰剂对照交叉研究纳入40例维持使用吗替麦考酚酯(MMF)或肠溶霉酚酸钠(EC-MPS)的肾移植和肝移植受者,旨在明确泮托拉唑对霉酚酸(MPA)及其代谢物MPA-葡萄糖醛酸苷(MPA-G)药代动力学的影响。结果显示,泮托拉唑显著降低MMF组MPA-AUC12h,而显著升高EC-MPS组MPA-AUC12h,对MPA-G无影响。

要点

  • 泮托拉唑显著降低MMF组MPA-AUC12h(P=0.004)。
  • 泮托拉唑显著升高EC-MPS组MPA-AUC12h(P=0.023)。
  • 泮托拉唑对MPA-G药代动力学无影响。

核心结论

  • 泮托拉唑与MMF联用显著降低MPA生物利用度,与EC-MPS联用则产生相反效应。
  • 临床医生在处方不同MPA制剂时应警惕此药物相互作用。

研究设计与样本

  • 多中心、随机、前瞻性、双盲、安慰剂对照交叉研究。
  • 筛查45例受者,随机40例(19例MMF,21例EC-MPS)。
  • 受者平均(标准差)年龄58(11)岁,移植后中位(四分位距)时间43(20-132)个月。

主要发现

  • MMF组MPA-AUC12h几何均值(95%CI):安慰剂53.9(44.0-65.9)mg*h/L vs 泮托拉唑43.8(35.6-53.4)mg*h/L,P=0.004。
  • EC-MPS组MPA-AUC12h几何均值(95%CI):安慰剂36.1(26.5-49.2)mg*h/L vs 泮托拉唑45.9(35.5-59.3)mg*h/L,P=0.023。
  • 泮托拉唑对两组MPA-G的药代动力学曲线均无影响。

临床怎么用

  • 使用MMF的移植受者联用泮托拉唑时需关注MPA暴露降低的可能。
  • 使用EC-MPS的移植受者联用泮托拉唑时需关注MPA暴露升高的可能。
  • 处方不同MPA制剂时应考虑此药物相互作用并监测MPA浓度。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Mycophenolic acid (MPA) is widely utilized as an immunosuppressant in kidney and liver transplantation, with reports suggesting an independent relationship between MPA concentrations and adverse allograft outcome. Proton-pump inhibitors (PPIs) may have variable effects on the absorption of different MPA formulations leading to differences in MPA exposure. METHODS: A multicentre, randomized, prospective, double-blind placebo-controlled cross-over study was conducted to determine the effect of the PPI pantoprazole on the MPA and its metabolite MPA-glucuronide (MPA-G) area under the curve (AUC) >12 h (MPA-AUC12 h) in recipients maintained on mycophenolate mofetil (MMF) or enteric-coated mycophenolate sodium (EC-MPS). We planned a priori to examine separately recipients maintained on MMF and EC-MPS for each pharmacokinetic parameter. The trial (and protocol) was registered with the Australian New Zealand Clinical Trials Registry on 24 March 2011, with the registration number of ACTRN12611000316909 ('IMPACT' study). RESULTS: Of the 45 recipients screened, 40 (19 MMF and 21 EC-MPS) were randomized. The mean (standard deviation) recipient age was 58 (11) years with a median (interquartile range) time post-transplant of 43 (20-132) months. For recipients on MMF, there was a significant reduction in the MPA-AUC12 h [geometric mean (95% confidence interval) placebo: 53.9 (44.0-65.9) mg*h/L versus pantoprazole: 43.8 (35.6-53.4) mg*h/L; P = 0.004] when pantoprazole was co-administered compared with placebo. In contrast, co-administration with pantoprazole significantly increased MPA-AUC12 h [placebo: 36.1 (26.5-49.2) mg*h/L versus pantoprazole: 45.9 (35.5-59.3) mg*h/L; P = 0.023] in those receiving EC-MPS. Pantoprazole had no effect on the pharmacokinetic profiles of MPA-G for either group. CONCLUSIONS: The co-administration of pantoprazole substantially reduced the bioavailability of MPA in patients maintained on MMF and had the opposite effect in patients maintained on EC-MPS, and therefore, clinicians should be cognizant of this drug interaction when prescribing the different MPA formulations.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Sunderland A, Russ G, Sallustio B, et al. Effect of the proton-pump Inhibitor pantoprazole on MycoPhenolic ACid exposure in kidney and liver transplant recipienTs (IMPACT study): a randomized trial. Nephrol Dial Transplant. 2020. PMID: 32516810. doi:10.1093/ndt/gfaa111

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。